- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01801137
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)
June 20, 2016 updated by: Hopital Foch
A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy
A study to determine the efficacy of Everolimus(Afinitor®) as third line therapy in patients with transitional cell carcinoma of the urothelium which failed or progressed after two lines of chemotherapy
Study Overview
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ile de France
-
Suresnes, Ile de France, France, 92150
- Hôpital FOCH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of written informed consent
- Male or female aged more than 18 years
- Histologically proven transitional cell carcinoma of the urothelium
- Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
- Recurrence or progression after at least one chemotherapy regimen and for unresectable/advanced disease
- No more than 2 lines of previous chemotherapy..
- Measurable disease (RECIST criteria)
- Previously irradiated lesions are not considered measurable- ECOG performance status of 0, 1 or 2
Exclusion Criteria:
- No prior treatment with anti cancer agents, including radiotherapy, in the last 4 weeks.
- No currently active CNS involvement
- No pregnancy. Women of child bearing potential must have a negative pregnancy test.
- No uncontrolled diabetes
- No symptomatic coronary artery disease, myocardial infarction within the last six months, congestive cardiac failure greater than New York Heart Association (NYHA) class II, uncontrolled or symptomatic cardiac arrhythmia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afinitor
Treatment by Afinitor 10 mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival rate at 12 weeks
Time Frame: 3 months
|
If a patient has not had an event, Progression-free survival is censored at the date of last adequate tumor assessment.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
February 12, 2013
First Submitted That Met QC Criteria
February 26, 2013
First Posted (Estimate)
February 28, 2013
Study Record Updates
Last Update Posted (Estimate)
June 21, 2016
Last Update Submitted That Met QC Criteria
June 20, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010/23
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Cancer
-
Spanish Oncology Genito-Urinary GroupBristol-Myers SquibbRecruiting
-
Astellas Pharma Global Development, Inc.Merck Sharp & Dohme LLC; Seagen Inc.RecruitingUrothelial CancerUnited States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
-
Fundacion CRIS de Investigación para Vencer el...GlaxoSmithKline; Apices Soluciones S.L.; IpsenActive, not recruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingUrothelial CancerGermany, Switzerland
-
University of ChicagoCompletedUrothelial CancerUnited States
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdActive, not recruitingUrothelial CancerRussian Federation, United States, Brazil, Spain, Chile, Korea, Republic of, Argentina, Australia, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Romania, Swed... and more
-
AstraZenecaActive, not recruitingUrothelial CancerUnited States, Belgium, Denmark, Germany, Italy, Spain, Canada, Poland, Taiwan, France, Korea, Republic of, Netherlands, United Kingdom, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Austria, Australia, Israel, Portugal, G...
-
Canadian Cancer Trials GroupCelgene; Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCompletedUrothelial CancerCanada, Australia
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingBladder Urothelial CancerChina
-
Gilead SciencesMerck KGaA, Darmstadt, GermanyRecruitingMetastatic Urothelial CancerItaly, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
Clinical Trials on Everolimus (Afinitor®)
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Dana-Farber Cancer InstituteNovartis PharmaceuticalsCompletedTuberous Sclerosis Complex | TSC1 | TSC2 | MTORUnited States
-
Swiss Group for Clinical Cancer ResearchCompletedProstate CancerSwitzerland
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHCompletedNeuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditionsGermany
-
Washington University School of MedicineTyrogenexTerminatedAdenocarcinoma | Pancreatic NeoplasmsUnited States
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKTerminatedMetastatic Clear Cell Renal CarcinomaUnited Kingdom
-
Novartis PharmaceuticalsCompleted
-
NYU Langone HealthCompletedEpilepsy | Tuberous Sclerosis Complex | Focal Cortical DysplasiaUnited States